10 / 510 5 7 8 DT04 Rec'd PCT/PTO 0 8 OCT 2004 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No.		:	PCT/EP2004/001370				
Intern	ternational Filing Date			:	13 February 2004 (13.02.2004)		
Priori	ty Date	(s) Clai	med	:	13 February 2003 (13.02.2003)		
Applicant(s) (DO/EO/US) :					Karlheinz DOSER et al.		
	-				AINING CLOPIDOGREL AND USE RMACEUTICAL FORMULATIONS		
INFO)RMA	TION E	DISCLOSUR	E STATEME	ENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98		
P.O. I	nissione Box 145 Indria, V	0	atents 13-1450				
Sir:							
and 1	This i .98 as fo		tion disclosure	e statement is r	made in accordance with 37 C.F.R. §§ 1.56, 1.97		
<u>Timir</u>	g and F	<u>ees</u>					
\boxtimes	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this inform disclosure statement is filed:						
			n three month: § 1.53(d);	s of the filing	date of a national application other than a CPA		
		within three months of the actual filing date of the national phase of a PO application; OR					
		before RCE)	_	of a first substa	antive office action (including after filing of an		
	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of:						
			a final rejec	tion under 37	C.F.R. 1.113;		
			termination OR	of prosecution	n, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
			a notice of a	allowance und	er 37 C.F.R. § 1.311; and		

10 / 510 578

	is accc	ompanied by:	DT04 Rec'd PCT/PTO 0 8 OCT
		the statement as specified in 37 C.F.R.	§ 1.97(e) set out below; OR
		a check covering the fee of \$180.00 un	der 37 C.F.R. § 1.17(p).
		R. § 1.97(d), this information disclosure lowing actions which have not been wit	
		a final action under 37 C.F.R. § 1.113;	
		termination of prosecution, e.g. Ex Par OR	rte Quayle, M.P.E.P § 609(B)(2);
		a notice of allowance under 37 C.F.R.	§ 1.311;
AND	is filed (on or before payment of the issue fee; A	ND is accompanied by:
		the statement as specified in 37 C.F.R. the fee of \$180.00 under 37 C.F.R. § 1	· ·
Statements U	nder 37	C.F.R. 1.97(e)	
		Each item of information contained statement was cited in a communicatio counterpart foreign application having months prior to the filing date of this in	n from a foreign patent office in a a mailing date not more than three
		No item of information contained in this was cited in a communication from a for foreign application, and to the knowled after making reasonable inquiry, no item information disclosure statement was kin 37 C.F.R. § 1.56(c) more than three the information disclosure statement.	reign patent office in a counterpart edge of the undersigned attorney m of information contained in this nown to any individual designated
Cited Materia	<u>ıls</u>		
		e cited in benefit (35 U.S.C. § 120) a 892 by the Examiner and/or Form b.	
\boxtimes	•	s of materials listed but not attached we dated August 10, 2004.	re cited in an international search
	Copies	s of the materials listed are attached (ex	cept for the foregoing).

10 / 510 578 DT04 Rec'd PCT/PTO 0 8 OCT 2004

Non-English Language References An English-language search report or equivalent paper from a foreign patent \Box office is provided indicating the relevance of the cited reference(s). \boxtimes A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below: X =document of particular relevance when it is taken alone document of particular relevance when it is combined with another such Y =document document defining the general state of the art A =O = non-written disclosure P =intercalated document T =document cited to understand the theory or principle underlying the patent document which has the benefit of a date earlier than the filing date $\mathbf{E} =$ and which was published only on or after this filing date cited in the application D =L =cited for another reason publication of member of same patent family & = \boxtimes Translation of other relevant information on foreign search report In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula 18, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example. Other Information Payment of Fees Due (If Any):

covering the fee identifie d above is attached.

Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.

A check for \$

10 / 510 578
DT04 Rec'd PCT/PT0 0 8 OCT 2004
The Commissioner is hereby authorized to charge or credit any overpayment to Deposit \boxtimes Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: LEDER-0011

Date: October 8, 2004

AJZ:ssr

DT04 Rec'd PCT/PTO 0 8 OCT 2004

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

0/510578 Substitute for form 1449A/PTO Complete if Known Application Number USNP of PCT/EP2004/001370 INFORMATION DISCLOSURE 13 February 2004 (13.02.2004) STATEMENT BY APPLICANT First Named Inventor Karlheinz DOSER et al. Group Art Unit unknown (use as many sheets as necessary) **Examiner Name** unknown Sheet of **LEDER-0011** Attorney Docket Number

	U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.¹	U.S. Patent Docum	nent Kind Code ² (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	001	2004/0024011		VALERIANO ET AL.	02-05-2004			
	002	4,847,265		BADORC ET AL.	07-11-1989			
	003	6,509,348		OGLETREE	01-21-2003			
	004	6,284,277		BOULOUMIE ET AL.	09-04-2001			
		24						

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т ⁶
	005	W0	2004/013147		TEVA PHARM. INC	02-12-2004		001
	006	EP	1161956		DAIICHI SEIYAKU CO	12-12-2001		
				ļ				

		$\overline{}$
Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.